Olanzapine and 5-HT3 With or Without Dexamethasone to Prevent CINV

Exclusion Criteria

• •1. There are contraindications to chemotherapy(Absolute number of neutrophils ≤ 1,500/uL, hemoglobin ≤ 90g/L, platelet count ≤ 10000/uL, serum creatinine level ≥ 2.0mg/dl (177 μmol/L), ALT and AST ≥ 2.5 times the upper normal limit, bilirubin ≥ 1.5 times the upper normal limit);
• •2. History of central nervous system disease (e.g., brain metastases or a seizure disorder);
• •3. Severe cognitive impairment；
• •4. Treatment with another antipsychotic agent such as risperidone, quetiapine, clozapine, a phenothiazine, or a butyrophenone within 30 days before enrollment or plans for such treatment during the study period;
• •5. Concurrent use of pharyngeal or abdominal radiotherapy;
• •6. Concurrent use of quinolone antibiotics;
• •7. Concurrent use of Amifostine;
• •8. Chronic alcoholism;
• •9. Known hypersensitivity to olanzapine;
• •10. Know arrhythmia, uncontrolled congestive heart failure or acute myocardial infarction within 6 months;
• •11. Known uncontrolled diabetes mellitus;
• •12. Vomiting or retching 24 hours before chemotherapy;
• •13. Use of anti-emesis drugs 48 hours before chemotherapy;
• •14. Patients who require medication with dexamethasone for pretreatment.